Intrahepatic cholangiocarcinoma with FGFR2 fusion gene positive that responded to pemigatinib and caused hypophosphatemia

Yoshinori Kikuchi; Kazuhisa Yamaguchi; Ryo Shimizu; Yuu Matsumoto; Yasuko Kurose; Naoki Okano; Yuichirou Otsuka; Kazutoshi Shibuya; Takahisa Matsuda; Hideaki Shimada

doi:10.1007/s13691-023-00619-5

Intrahepatic cholangiocarcinoma with FGFR2 fusion gene positive that responded to pemigatinib and caused hypophosphatemia

Int Cancer Conf J. 2023 Jul 3;12(4):285-290. doi: 10.1007/s13691-023-00619-5. eCollection 2023 Oct.

Affiliations

¹ Department of Clinical Oncology, Toho University, 6-11-1 Omori-nishi, Ota-ku, Tokyo, 143-8541 Japan.
² Division of Gastroenterology and Hepatology, Department of Internal Medicine (Omori), Toho University, Tokyo, Japan.
³ Division of General and Gastroenterological Surgery, Department of Surgery (Omori), Toho University, Tokyo, Japan.
⁴ Department of Surgical Pathology (Omori), Toho University, Tokyo, Japan.

Abstract

Intrahepatic cholangiocarcinoma is a condition with a poor prognosis. Traditionally, there was no cure unless important drugs such as gemcitabine, cisplatin, and tegafur/gimeracil/uracil potassium showed efficacy. Pemigatinib has recently become accessible for the treatment of intrahepatic cholangiocarcinoma with FGFR2 fusion or rearrangement gene abnormalities. Hyperphosphatemia is typically linked to pemigatinib. In the current case, pemigatinib was used to effectively treat a 48-year-old woman, and hypophosphatemia was observed. Patients with intrahepatic cholangiocarcinoma should undergo aggressive cancer multigene panel testing as well as careful monitoring of serum phosphorus levels.

Keywords: Chemotherapy; Fibroblast growth factor receptor 2 fusion gene; Intrahepatic cholangiocarcinoma; Pemigatinib.

© The Author(s) under exclusive licence to The Japan Society of Clinical Oncology 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.